Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...4344454647484950515253...208209»
  • ||||||||||  eribulin liposome (HR19024) / Jiangsu Hengrui Pharma
    Trial completion, Phase classification, Enrollment change, Trial completion date, Trial primary completion date:  A Study of HR19024 in Subjects With Advanced Solid Tumor (clinicaltrials.gov) -  Mar 20, 2025   
    P1,  N=71, Completed, 
    However, pyrotinib plus trastuzumab did not show better efficacy compared with Per Recruiting --> Completed | Phase classification: P1a --> P1 | N=180 --> 71 | Trial completion date: Jul 2023 --> Oct 2024 | Trial primary completion date: Jul 2023 --> Oct 2024
  • ||||||||||  HRS-1780 / Jiangsu Hengrui Pharma, Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
    Enrollment closed, Trial primary completion date:  Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease (clinicaltrials.gov) -  Mar 20, 2025   
    P2,  N=181, Active, not recruiting, 
    Recruiting --> Completed | Phase classification: P1a --> P1 | N=180 --> 71 | Trial completion date: Jul 2023 --> Oct 2024 | Trial primary completion date: Jul 2023 --> Oct 2024 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2024 --> Mar 2025
  • ||||||||||  Enrollment open:  A Trial of SHR0302Base in Patients With Vitiligo (clinicaltrials.gov) -  Mar 19, 2025   
    P2,  N=152, Recruiting, 
    Lenvatinib/bevacizumab combined with programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors and gemcitabine/oxaliplatin (GEMOX) represent an effective and tolerable regimen for advanced BTC in a multicenter retrospective real-world study. Not yet recruiting --> Recruiting
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, PD(L)-1 Biomarker, IO biomarker:  Clinical efficacy and safety of transarterial chemoembolization combined with targeted therapy and PD1 inhibitors in patients with advanced liver cancer. (Pubmed Central) -  Mar 19, 2025   
    The overall response rate(ORR) was 80% in the experimental group and 62% in the control group, and the difference was statistically significant(p=0.03); the incidence of adverse reactions was 28% in the experimental group and 25% in the control group, with no significant difference between the two groups(p=0.68); the improvement rate of QOL score was significantly increased(p=0.03) and the deterioration rate was significantly decreased(p=0.01) in the experimental group compared with those in the control group, respectively. TACE combined with targeted therapy and PD1 inhibitors is significantly effective to improve the cellular immune function with no significant increase in the incidence of adverse reactions, making it an effective and safe treatment option for patients with liver cancer.
  • ||||||||||  carfilzomib / Generic mfg., HRS-4642 / Jiangsu Hengrui Pharma
    Journal:  New exploration of KRASG12D inhibitors and the mechanisms of resistance. (Pubmed Central) -  Mar 18, 2025   
    Here, we aim to describe a potential novel therapy for patients with KRASG12D mutations and present the first KRASG12D-specific inhibitor to be proven as clinically effective. Different mutations of KRAS gene and mechanisms of KRAS drug resistance were also discussed.
  • ||||||||||  AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, HRS-1358 / Jiangsu Hengrui Pharma
    Trial primary completion date, Monotherapy:  A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer (clinicaltrials.gov) -  Mar 17, 2025   
    P1,  N=102, Recruiting, 
    Not yet recruiting --> Recruiting Trial primary completion date: Dec 2024 --> Jun 2025
  • ||||||||||  AiRuiKa (camrelizumab) / Elevar Therapeutics
    Trial completion date, Trial initiation date, Trial primary completion date:  A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC (clinicaltrials.gov) -  Mar 17, 2025   
    P2,  N=60, Not yet recruiting, 
    Trial primary completion date: Dec 2024 --> Jun 2025 Trial completion date: Dec 2026 --> Mar 2027 | Initiation date: Oct 2024 --> Apr 2025 | Trial primary completion date: Dec 2026 --> Mar 2027
  • ||||||||||  paclitaxel / Generic mfg., AiRuiKa (camrelizumab) / HLB Bio Group
    Journal, Checkpoint inhibition:  Dermatitis bullosa caused by the immune checkpoint inhibitor camrelizumab: A case report. (Pubmed Central) -  Mar 17, 2025   
    Early recognition and accurate diagnosis, combined with interdisciplinary collaboration and swift initiation of immunosuppressive therapy, are essential in managing severe immune-related adverse reactions effectively. This report details the treatment trajectory and outcome of a case involving immune-related cutaneous adverse reactions, providing pertinent clinical insights for future cases.
  • ||||||||||  Shudi Insulin Injection (long-acting basal insulin analog) / Jiangsu Hengrui Pharma
    Trial completion, Trial completion date, Trial primary completion date:  To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin. (clinicaltrials.gov) -  Mar 13, 2025   
    P3,  N=423, Completed, 
    Camrelizumab combined with platinum-based chemotherapy is effective and well-tolerated as the first-line treatment for ESCC, and IRS may reveal mechanism influencing treatment response. Recruiting --> Completed | Trial completion date: Oct 2024 --> Jun 2024 | Trial primary completion date: Oct 2024 --> Jun 2024
  • ||||||||||  AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
    Enrollment open:  Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer (clinicaltrials.gov) -  Mar 13, 2025   
    P2,  N=30, Recruiting, 
    Recruiting --> Completed | Trial completion date: Oct 2024 --> Jun 2024 | Trial primary completion date: Oct 2024 --> Jun 2024 Not yet recruiting --> Recruiting
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Journal:  Cocry-pred: A Dynamic Resource Propagation Method for Cocrystal Prediction. (Pubmed Central) -  Mar 12, 2025   
    Subsequently, seven Apatinib cocrystals were then synthesized experimentally, among which single-crystal structures were obtained for two cocrystals. This advancement highlights the potential of Cocry-pred as a powerful tool, offering significant improvements in efficiency and providing valuable insights for cocrystal screening and design.
  • ||||||||||  Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
    Trial completion, Trial completion date, Trial primary completion date:  Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM (clinicaltrials.gov) -  Mar 12, 2025   
    P4,  N=210, Completed, 
    Recruiting --> Completed | Trial completion date: Aug 2022 --> Jul 2024 | Trial primary completion date: Aug 2021 --> Jul 2024 Recruiting --> Completed | Trial completion date: Aug 2024 --> Oct 2024 | Trial primary completion date: Jul 2024 --> Oct 2024
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Biomarker, PD(L)-1 Biomarker, IO biomarker:  Case Report: Complete response to four cycles of camrelizumab in a PD-L1 negative patient with advanced oral squamous cancer. (Pubmed Central) -  Mar 11, 2025   
    This situation has not been reported previously, suggesting that some patients can benefit from short-term immunotherapy and even achieve CR; moreover, there may be more molecular markers to be discovered that can predict the efficacy of immunotherapy. We can conduct in-depth research on relevant molecular markers, formulate personalized immunotherapy strategies and plans, and facilitate the development of new precision treatment strategies for HNSCC.